Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Launches a New Educational Website 'So-Zo LABO' Aiming for a Society that Embraces Diversity

12/02/2021 | 08:26am EST

TOKYO - Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that the company has launched an educational website for kids 'So-Zo LABO by a Pharmaceutical Company for the Body, Mind, and Everyone' (hereafter, 'So-Zo LABO') to ensure that children understand about diseases correctly, imagine the feelings of those who have the illness, and create a healthy society that embraces the diversity.

The specific contents of the So-Zo LABO include diseases common among children and affect many of them as a tool to help children understand each disease correctly. The 'Mechanisms of Disease' addresses four disease areas, infection, cancer, immune disorders, and genetic disease. The website provides easy-to-understand explanations of the development and treatment of each disease using illustrations.

In addition, 'If I were you,' a cartoon content featuring grade school students, was selected for 'atopic dermatitis' and 'cancer' to foster imagination and compassion for the feelings of people with diseases so that they can learn about the daily lives of people with the illness and consider it as their own.

Main Contents of the 'So-Zo LABO'

1. Mechanism of Disease: content that teaches how diseases occur and how to treat them, including infection, cancer, immune disorders, and genetic disease.

2. If I were you: content to help children understand the various symptoms, imagine the feelings of people with diseases, and develop a sense of compassion through cartoons depicting the daily lives of people with diseases (episode one: atopic dermatitis, episode two: cancer)

3. What is a disease?: message content presented by educators for children to think about illness

4. The street of medicine 'CHUGAI': content to learn about medicines and Chugai Pharmaceutical

5. Explore SDGs: content to learn SDGs in general, including Chugai initiatives

Contact:

Media

Chugai Pharmaceutical Co., Ltd.

Media Relations Group

Corporate Communications Dept.

Tomoko Shimizu

Tel: +81-3-3273-0881

E-mail: pr@chugai-pharm.co.jp

Investors

Chugai Pharmaceutical Co., Ltd.

Investor Relations Group

Corporate Communications Dept.

Takayuki Sakurai

Tel: +81-3-3273-0554

E-mail: ir@chugai-pharm.co.jp

(C) 2021 Electronic News Publishing, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
CHUGAI PHARMACEUTICAL CO., LTD -0.24% 3680 Delayed Quote.-1.23%
ROCHE HOLDING AG -0.88% 362.3 Delayed Quote.-3.69%
All news about CHUGAI PHARMACEUTICAL CO., LTD
02:12aCHUGAI PHARMACEUTICAL : Actemra Approved for Additional Indication of SARS-CoV-2 Pneumonia..
PU
2021CHUGAI PHARMACEUTICAL CO., LTD. : Ex-dividend day for final dividend
FA
2021CHUGAI PHARMACEUTICAL : Signs Joint Research Agreement with NCC for Asian International Co..
PU
2021Launch of Chugai's New TV Commercial 'Protect the Ordinary Days People Cherish' Featuri..
AQ
2021CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for Additional Indi..
PU
2021CHUGAI PHARMACEUTICAL : Launch of Chugai's New TV Commercial “Protect the Ordinary D..
PU
2021Chugai Pharmaceutical Co., Ltd. - Notice of Board of Director's Resolution on Applicati..
AQ
2021Chugai Obtained Highest A-Rating by CDP in Two Categories and SBT Validation for Greenh..
AQ
2021Chugai Pharmaceutical Co. - Update on the Development of Oral COVID-19 Drug Candidate A..
AQ
2021Nikkei 225 Declines 1.8% on Central Bank Outlooks
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2021 975 B 8 575 M 8 575 M
Net income 2021 292 B 2 568 M 2 568 M
Net cash 2021 461 B 4 055 M 4 055 M
P/E ratio 2021 20,8x
Yield 2021 1,87%
Capitalization 6 051 B 53 066 M 53 199 M
EV / Sales 2021 5,73x
EV / Sales 2022 5,37x
Nbr of Employees 7 555
Free-Float -
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 689,00 JPY
Average target price 4 823,85 JPY
Spread / Average Target 30,8%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-1.23%53 196
JOHNSON & JOHNSON-3.40%435 037
ROCHE HOLDING AG-3.69%322 260
PFIZER, INC.-8.47%303 375
ABBVIE INC.-1.75%235 181
NOVO NORDISK A/S-13.40%220 833